When operating room delays and tray errors threatened efficiency, leaders at New York Presbyterian built a collaborative bridge with central sterile processing. Through shared metrics, workflow exchanges, and improved communication, first-case-on-time starts climbed from the 50 to nearly 90%.
When a nationwide blood-culture bottle shortage squeezed hospitals, a Stanford-led team turned to machine learning by building and openly sharing tools that predict which patients are most likely to have bacteremia and when a culture can be safely deferred. The simplest version works as a quick bedside score, no new software required.
A Bangladesh research team unveiled a suitcase-sized, point-of-care test that detects Nipah virus from respiratory patients in about 30 minutes, showing accuracy comparable to RT-PCR, and designed to bring rapid diagnosis and outbreak control to rural, low-resource settings.
From hand-hygiene audits to the SHEA Board of Trustees, the professional path of Alexander Sundermann, DrPH, CIC, FAPIC, AL-CIP, traces the arc of modern infection prevention. The former hospital IP—now a University of Pittsburgh assistant professor—pairs frontline experience with genomic epidemiology to turn sequencing into outbreak-stopping action.
When Hurricane Helene flooded a North Carolina facility and sparked an IV fluid shortage, Duke’s stewardship network turned crisis into practice change—rapidly shifting eligible patients to highly bioavailable oral antibiotics and boosting PO use by 5.6% across participating hospitals.
At IDWeek in Atlanta, former CDC director Tom Frieden unveiled a crisp playbook for infection prevention—“See. Believe. Create.”—arguing it can help hospitals spot outbreaks sooner, reverse drug resistance, and drive HAIs toward zero. He paired the message with a 7-1-7 target: 7 days to find an outbreak, 1 to report, 7 to control.
IDWeek 2024 continues to give encouraging studies. Check out several more from CSL Seqirus and Shionogi.
Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.
Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.
Peter Rabinowitz, MD, MPH, discusses how climate change, including extreme weather and temperature shifts, is reshaping the spread of infectious diseases like dengue, leptospirosis, and Valley fever.
The rise of multidrug-resistant gonorrhea highlights the urgent need for new therapies. Zoliflodacin, a promising oral antibiotic, shows effectiveness in late-stage trials.
Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending October 29, 2023.
Staying Ahead With Company Updates and Product Innovations. This week's news is from Moderna, CBIC, Helocyte, Pfizer, UVDI, and CloroxPro.
Benjamin Chen, MD, MPH, speaks about how a journal watch in infection prevention keeps professionals updated on research, fosters evidence-based practices, and supports education and quality improvement efforts.
Recent INFORM and EPOCH studies shed light on the significant risk and poor outcomes faced by immunocompromised individuals due to COVID-19, emphasizing the need for tailored prevention strategies.
At IDWeek 2023, a presenter uses HIV as a model to understand the post-acute sequelae of viral infections.
At IDWeek 2023, a session illuminates the importance of accurate diagnosis, current treatments, and what is on the horizon for HSV.
Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA, and SHEA Chair, highlights IDWeek 2023's hybrid format and discusses the critical topic of antimicrobial resistance, emphasizing the role of vaccines in reducing AMR.
The latest news on CLABSIs in the pediatric population is presented at IDWeek 2023.
At IDWeek 2023, a look into managing VAIs in children.
Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending October 15, 2023.
A study in Maryland from June 2019 to December 2021 analyzed 140 Candida auris cases, revealing that patients often resided in disadvantaged neighborhoods with higher crowding, uninsured rates, and racial diversity. ICT speaks to the lead author.
A phase 3 trial presented at IDWeek 2023 shows that sulbactam-durlobactam (SUL-DUR) reduces mortality and improves outcomes in hospital-acquired Acinetobacter baumannii-calcoaceticus complex infections compared to colistin, offering a promising treatment option.
Dr. Isaac Kohane explores AI's rapid medical evolution and the challenges of accuracy, updating, and education in infectious diseases at IDWeek 2023.
BiomX Develops BX004-A, a Phage Therapy, for Cystic Fibrosis Patients with Pseudomonas Infections. A phase 1b/2a study presents promising results at IDWeek 2023.
Wastewater-based surveillance can accurately monitor influenza A and B and RSV at the population level. This makes it an objective tool to inform public response to common seasonal illnesses.
The investigational mRNA-1647 vaccine discussed at IDWeek 2023 shows great promise in the fight against cytomegalovirus (CMV) infection. Developed using messenger RNA technology, it incorporates essential CMV antigens and has demonstrated safety and effectiveness in clinical evaluations.
This edition of Infection Intel from Infection Control Today covers infection control and prevention company news out of IDWeek, being held in Boston, Massachusetts, from October 11 to 15, 2023.
Most often, the first place a patient enters a hospital is through the emergency department and sometimes by emergency medical services. Where else to better stop Clostridioides difficile from coming into the hospital than at the entrance?
